Biotech week ahead, March 2

Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved advantageous for some biotechs that disclosed plans to work on therapies or vaccines for countering the viral attack.
The FDA approved Esperion Therapeutics Inc’s ESPR 3.46% LDL-cholesterol lowering combo therapy and Biohaven Pharmaceutical Holding Co Ltd’s BHVN 8.24% migraine drug.
The following are key catalysts that could move biotech stocks in the unfolding week.

Conferences

Cowen 40th Annual Healthcare Conference: March 2-4 in Boston, Massachusetts

Earnings

Monday

• Albireo Pharma Inc ALBO 2.9% (before the market open)
• Amicus Therapeutics, Inc. FOLD 2.25% (before the market open)
• Intra-Cellular Therapies Inc ITCI 3.03% (before the market open)
• Seres Therapeutics Inc MCRB 8.19% (before the market open)
• Urogen Pharma Ltd URGN 1.83% (before the market open)
• Wave Life Sciences Ltd WVE 7.52% (before the market open)
• Fate Therapeutics Inc FATE 1.42% (after the close)
• FibroGen Inc FGEN 3.06% (after the close)
• GenMark Diagnostics, Inc GNMK 3.59% (after the close)
• Omeros Corporation OMER 0.34% (after the close)
• PTC Therapeutics, Inc. PTCT 2.43% (after the close)
• Precigen Inc PGEN 1.88% (after the close)
• ZIOPHARM Oncology Inc. ZIOP 3.34% (after the close)
• Zogenix, Inc. ZGNX 5.87% (after the close)

Tuesday

• Antares Pharma Inc ATRS 3.33% (before the market open)
• Autolus Therapeutics Ltd – ADR AUTL 4.88% (before the market open)
• Neuronetics Inc STIM 1.86% (before the market open)
• TG Therapeutics Inc common stock TGTX 1.21% (before the market open)
• Sierra Oncology Inc SRRA 7.2% (before the market open)
• Infinity Pharmaceuticals Inc. INFI 3.31% (after the close)
• Syndax Pharmaceuticals Inc SNDX 12.47% (after the close)
• VIVUS, Inc. VVUS 3.21% (after the close)
• Voyager Therapeutics Inc VYGR 2.83% (after the close)
• DURECT Corporation DRRX 0.56% (after the close)
• Cytokinetics, Inc. CYTK 0.04% (after the close)

Wednesday

• Axonics Modulation Technologies Inc AXNX 0.98% (after the close)
• Orthopediatrics Corp KIDS 4.74% (after the close)
• Opiant Pharmaceuticals Inc OPNT 0.17% (after the close)

Thursday

• Arbutus Biopharma Corp ABUS 5.81% (before the market open)
• BioCryst Pharmaceuticals, Inc. BCRX 9.29% (before the market open)
• Eyepoint Pharmaceuticals Inc EYPT (before the market open)
• Xtant Medical Holdings Inc XTNT 19.58% (before the market open)
• Fulcrum Therapeutics Inc FULC 2.88% (before the market open)
• Syros Pharmaceuticals Inc SYRS 12.03% (before the market open)
• Obseva SA OBSV 0.98% (before the market open)
• OptiNose Inc OPTN 6.2% (before the market open)
• Caladrius Biosciences Inc CLBS 0.79% (after the close)
• Eton Pharmaceuticals Inc ETON 0.74% (after the close)

IPO Quiet Period Expiry

Beam Therapeutics Inc BEAM 1.92%
PPD Inc PPD 2.38%

Apart from scheduled catalysts, any company updates on COVID-19 programs could be of interest for investors given the potential for big swings.
https://www.benzinga.com/general/biotech/20/02/15443793/the-week-ahead-in-biotech-covid-19-stocks-in-the-spotlight-earnings-taper-off